Ammonium glycyrrhizate
CAS 53956-04-0
Ammonium glycyrrhizate (CAS 53956-04-0) is a pharmaceutical compound with 0 bioactivity targets and 41 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Ammonium glycyrrhizate is linked to DTXSID2041204 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| AMMONIUM GLYCYRRHIZATE | 1311505 | SU | MTHSPL |
| ammonium glycyrrhizate | 1311505 | SU | MTHSPL |
| Ammonium Glycyrrhizate | 1311505 | SU | MTHSPL |
| ammonium glycyrrhizate | 1311505 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ammonium glycyrrhizate used for in pharmaceutical contexts?
Ammonium glycyrrhizate (CAS 53956-04-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ammonium glycyrrhizate?
Ammonium glycyrrhizate has 41 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Benign prostatic hyperplasia, Calculus bladder, Cholangitis, Off label use, Pleural effusion. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ammonium glycyrrhizate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ammonium Glycyrrhizate with EU status "permitted".
What clinical phase is Ammonium glycyrrhizate in?
No phase 1-4 clinical development badge is rendered for Ammonium glycyrrhizate because the matched compound identifier rows do not contain a max-phase value.